undamentalytics Newsletter
Sign in

Protalix Biotherapeutics, Inc. income statement

In fiscal 2025, Protalix Biotherapeutics, Inc. reported revenue of $52.7m, down 1.2% on the year before, operating income of −$5.5m (a -10.4% margin) and net income of −$6.6m, or −$0.08 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue07835044921345563384865535381
Cost of revenue442801181591111162023242725
Gross profit−3712603414254452222843292656
Research and development273838372927253032334538302917132020
Selling, general and administrative———10897912111011131215121213
General and administrative777———————————————
Operating income−32−30−37−12−34−29−24−33−35−19−113−20−13104−623
Interest expense————144———————————
Income before tax———————————−7−28−1494−623
Income tax—————————————10115
Net income−31−29−37−12−28−3058−29−83−26−18−7−28−1583−719
Diluted EPS$0.20−$1.80−$2.15−$0.65−$1.50−$1.60$3.05−$1.45−$3.19−$0.90−$0.61−$0.22−$0.62−$0.31$0.09$0.04−$0.08$0.24
Diluted shares (average)—16m17m18m18m19m19m20m26m29m30m29m44m48m82m81m79m80m
EBITDA———−8−31−25−21−31−33−18−94−19−12125−425

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AAPG vs PLXADCT vs PLXBCYC vs PLXPLX vs VSTM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Protalix Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Protalix Biotherapeutics, Inc.